DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis

Alnylam Pharmaceuticals

Status: Completed

Conditions: Familial Amyloidotic Cardiomyopathy (FAC)

Study type: Observational

Funder types: Industry

Identifiers

NCT02252653

ALN-TTR-NT-002

Details and patient eligibility

About

The purpose of this study is to characterize the frequency of TTR mutations in subjects suspected of having cardiac amyloidosis

Enrollment: 1,010 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males or females >18 years old
• History of evidence suggestive of cardiac amyloidosis
• Subject is willing and able to comply with protocol required assessments and provide written informed consent

Exclusion criteria

• Known diagnosis of primary (AL) amyloidosis
• Known diagnosis of hereditary cardiomyopathy or cardiomyopathy due to aortic stenosis
• Patient is currently pregnant

Trial design

1,010 participants in 1 patient group

Familial Amyloidotic Cardiomyopathy (FAC)